Urticaria News and Research

RSS
Urticaria are itchy, raised red areas on the skin. Urticaria are caused by a reaction to certain foods, drugs, infections, or emotional stress. Also called hives.
FDA approves Iroko Pharmaceuticals’ ZORVOLEX capsules

FDA approves Iroko Pharmaceuticals’ ZORVOLEX capsules

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

FDA accepts, files Genentech's sBLA for subcutaneous use of Xolair in people with CIU

FDA accepts, files Genentech's sBLA for subcutaneous use of Xolair in people with CIU

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

Data shows individualized regimens can help optimize prophylaxis treatment in hemophilia patients

Data shows individualized regimens can help optimize prophylaxis treatment in hemophilia patients

Shire's scientific data on treatments for psychiatric disorders to be presented at APA meeting

Shire's scientific data on treatments for psychiatric disorders to be presented at APA meeting

Boehringer Ingelheim updates HCPs, patients on COMBIVENT RESPIMAT Inhalation Spray

Boehringer Ingelheim updates HCPs, patients on COMBIVENT RESPIMAT Inhalation Spray

Data from MK-5172 Phase II study for treatment of HCV genotype 1 infection to be presented at EASL meeting

Data from MK-5172 Phase II study for treatment of HCV genotype 1 infection to be presented at EASL meeting

New data on Merck’s VICTRELIS for chronic HCV to be presented at EASL annual meeting

New data on Merck’s VICTRELIS for chronic HCV to be presented at EASL annual meeting

Tris Pharma gets FDA NDA approval for Karbinal ER Extended-release Oral Suspension

Tris Pharma gets FDA NDA approval for Karbinal ER Extended-release Oral Suspension

GE Healthcare seeks approval to supply Optison to EU market from Oslo manufacturing facility

GE Healthcare seeks approval to supply Optison to EU market from Oslo manufacturing facility

Study: Drug normally used to treat severe bronchial asthma beneficial for chronic urticaria sufferers

Study: Drug normally used to treat severe bronchial asthma beneficial for chronic urticaria sufferers

Omalizumab scratches the itch for urticaria patients

Omalizumab scratches the itch for urticaria patients

Otsuka receives FDA approval for ABILIFY MAINTENA to treat schizophrenia

Otsuka receives FDA approval for ABILIFY MAINTENA to treat schizophrenia

Baxter files FEIBA NF BLA with FDA for prophylactic treatment of hemophilia A or B

Baxter files FEIBA NF BLA with FDA for prophylactic treatment of hemophilia A or B

Omalizumab fast, safe and well-tolerated in teens and adults with chronic spontaneous urticaria

Omalizumab fast, safe and well-tolerated in teens and adults with chronic spontaneous urticaria

FDA approves new vial size for CSL Behring’s Privigen to treat primary immunodeficiency

FDA approves new vial size for CSL Behring’s Privigen to treat primary immunodeficiency

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

rEVO Biologics announces results from Atryn phase 3 studies on pregnant AT-deficient women

rEVO Biologics announces results from Atryn phase 3 studies on pregnant AT-deficient women

AMAG seeks FDA sNDA approval for Feraheme Injection

AMAG seeks FDA sNDA approval for Feraheme Injection